DNMT3A and acute myeloid leukemia: Rau et al. (2016) present a study in Blood that suggests that the histone lysine methyltransferase, disruptor of telomeric silencing 1-like (DOT1L) may represent a promising target in cases of DNMT3A-mutant AML.